Revenue and Business Performance - The "Internet+" services segment became the primary revenue source for the company, driven by the ongoing demand for epidemic prevention materials, resulting in a year-on-year increase in supply chain business revenue[9]. - The personal protective equipment (PPE) business experienced a contraction in revenue compared to the previous year, primarily due to the completion of a one-year local mask production subsidy program by the Hong Kong government[11]. - The group recorded revenue of HKD 41,000,000 for the year ended June 30, 2022, a decrease of 47% compared to HKD 77,800,000 in the same period of 2021[16]. - Gross profit for the same period was HKD 5,900,000, down 71% from HKD 20,900,000 in 2021[16]. - The group reported a loss attributable to equity holders of HKD 88,000,000, a 17% decrease from a loss of HKD 106,300,000 in the previous year[17]. - The "Internet+" supply chain services generated revenue of HKD 29,700,000, an increase of 138% from HKD 12,400,000 in the previous fiscal year[18]. - Revenue from personal protective equipment was HKD 9,100,000, a decrease of 86% from HKD 63,400,000 in the previous fiscal year[19]. Business Strategy and Development - The company has entered into commercial contracts with multiple enterprises in various provinces for innovative anti-counterfeiting products, covering industries such as tea and health food, with several batches of products delivered during the review period[10]. - The group plans to explore further opportunities in "Internet+" business development, particularly in healthcare-related platforms[15]. - The group signed service agreements with various platforms and brands to enhance its supply chain services, including partnerships with major beauty brands and a well-known skincare brand[14]. - The company is committed to developing and promoting its anti-counterfeiting business through the issuance of convertible bonds[39]. - The company is focused on expanding its e-commerce capabilities and enhancing its supply chain efficiency to meet growing market demands[52]. Financial Position and Capital Management - As of June 30, 2022, the group's bank balances and cash amounted to HKD 3,000,000, down from HKD 7,500,000 in 2021[26]. - Current assets totaled HKD 48,100,000, a slight decrease from HKD 49,600,000 in the previous year[26]. - Current liabilities were HKD 250,300,000, down from HKD 272,900,000 in 2021, resulting in a capital-to-debt ratio of 59% compared to 74% in the previous year[26]. - The company issued convertible bonds with a principal amount of HKD 89,625,000, which can be converted into a maximum of 150,000,000 shares at a conversion price of HKD 0.598 per share[31]. - The company issued a total of 263,602,941 shares upon full conversion of the convertible bonds at a revised conversion price of HKD 0.34 per share[34]. - The company has not received any default notices from bondholders and is in discussions for renewal or further extension of the convertible bonds[38]. Corporate Governance and Management - The company is committed to maintaining high levels of corporate governance and emphasizes the importance of a high-quality board composition, effective accountability systems, and a sound corporate culture to protect shareholder interests and enhance business growth[54]. - The board includes members with extensive academic and professional backgrounds, ensuring a diverse range of insights and expertise in decision-making processes[48][49]. - The independent non-executive directors play a crucial role in the audit and remuneration committees, ensuring transparency and accountability in financial reporting and executive compensation[48][49]. - The company has adopted and complied with the applicable code provisions of the GEM Listing Rules Appendix 15, with some deviations noted[55]. - The board is responsible for reviewing the group's financial performance and approving strategic plans and major investments[59]. Risk Management and Compliance - The company faces risks related to the lottery industry trends and regulations, which could adversely affect its operations and financial performance[95]. - The company has a structured approach to the appointment and re-election of directors at the annual general meeting[62]. - The board conducts annual reviews of the effectiveness of the risk management and internal control systems[81]. - The company has a dedicated internal audit function to independently assess the adequacy and effectiveness of its risk management and internal control systems[82]. Environmental and Social Responsibility - The company has implemented energy-saving measures to reduce greenhouse gas emissions, which are the primary source of its carbon footprint[186]. - The company has adopted responsible waste management policies to minimize waste generation and promote recycling[186]. - Nitrogen oxides emissions decreased from 5,639.03 grams in 2021 to 2,794.00 grams in 2022, a reduction of approximately 50.5%[187]. - Carbon dioxide emissions from vehicle fuel combustion fell significantly from 16,936.45 kilograms in 2021 to 1,511.06 kilograms in 2022, a reduction of approximately 91.1%[189]. - The company aims to maintain the electricity consumption density per production line below 14.83 kilowatt-hours, achieving 12.82 kilowatt-hours in 2022[199].
国药科技股份(08156) - 2022 - 年度财报